HALO
Halozyme Therapeutics, Inc.
$39.9
Earnings Summary
Revenue | $216.03Mn |
Net Profits | $81.84Mn |
Net Profit Margins | 37.88% |
Highlights
Halozyme Therapeutics, Inc.’s revenue jumped 3.38% since last year same period to $216.03Mn in the Q3 2023. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -2.26% fall in its revenue since last 3-months.
Halozyme Therapeutics, Inc.’s net profit jumped 32.78% since last year same period to $81.84Mn in the Q3 2023. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 9.48% jump in its net profits since last 3-months.
Halozyme Therapeutics, Inc.’s net profit margin jumped 28.44% since last year same period to 37.88% in the Q3 2023. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 12.01% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Halozyme Therapeutics, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | 0.8 |
EPS Estimate Current Year | 0.8 |
Highlights
Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.8 - a 12.68% jump from last quarter’s estimates.
Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.8.
Key Ratios
Key ratios of the Halozyme Therapeutics, Inc. post its Q3 2023 earnings
Earning Per Share (EPS) | 0.75 |
Highlights
Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 1.35% since last year same period to 0.75 in the Q3 2023. This indicates that the Halozyme Therapeutics, Inc. has generated 1.35% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-08-08 | 0.63 | 0.74 | 17.46% |
2023-05-09 | 0.48 | 0.47 | -2.08% |
2023-11-06 | 0.71 | 0.75 | 5.63% |
₹0 US Stocks a/c Opening Fee